Thermal-sensitive hydrogel as adjuvant-free vaccine delivery system for H5N1 intranasal immunization

Biomaterials

Volumn 33, Issue 7, 2012, Pages 2351-2360

  Wu, Youbin ^a,b   Wei, Wei ^a   Zhou, Meng ^a   Wang, Yueqi ^a,b   Wu, Jie ^a   Ma, Guanghui ^a   Su, Zhiguo ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Adjuvant free; H5N1 split antigen; Intranasal immunization; Thermal sensitive hydrogel; Vaccine delivery system

Indexed keywords

ADJUVANT-FREE; BODY TEMPERATURE; CYTOKINES; EPITHELIAL TISSUE; GLYCEROPHOSPHATE; IMMUNE MEMORY; IMMUNE RESPONSE; INTRANASAL; LYMPHOID TISSUE; NASAL CAVITY; RESIDENCE TIME; ROOM TEMPERATURE; T CELLS; THERMAL-SENSITIVE; TRANSEPITHELIAL TRANSPORT; VACCINE DELIVERY SYSTEM;

CHLORINE COMPOUNDS; HYDROGELS; IMMUNIZATION; PHOSPHOLIPIDS; TISSUE; TRANSPORTATION ROUTES; VACCINES;

ANTIGENS;

CHITOSAN DERIVATIVE; GAMMA INTERFERON; GLYCEROPHOSPHATE; IMMUNOGLOBULIN A; INFLUENZA VACCINE; INTERLEUKIN 4; N [(2 HYDROXY 3 TRIMETHYLAMMONIUM)PROPYL]CHITOSAN CHLORIDE; PROTEIN ZO1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY TEMPERATURE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; EPITHELIUM; FEMALE; HUMORAL IMMUNITY; HYDROGEL; IMMUNE RESPONSE; INFLUENZA A (H5N1); INFLUENZA VACCINATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; ROOM TEMPERATURE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIGENS, VIRAL; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHITOSAN; HUMANS; HYDROGELS; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MATERIALS TESTING; MICE; NASAL MUCOSA; TEMPERATURE; VACCINATION;

EID: 84855749021     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.11.068     Document Type: Article

References (32)

1. Song J.M., Kim Y.C., Lipatov A.S., Pearton M., Davis C.T., Yoo D.G., et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B- and T-cell responses in mice. Clin Vaccine Immunol 2010, 17:1381-1389.
2. Barackman J.D., Ott G., O'Hagan D.T. Intranasal immunization of mice with influenza vaccine in combination with the adjuvant LT-R72 induces potent mucosal and serum immunity which is stronger than that with traditional intramuscular immunization. Infect Immun 1999, 67:4276-4279.
3. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
4. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11:S45-S53.
5. Brandtzaeg P. Induction of secretory immunity and memory at mucosal surfaces. Vaccine 2007, 25:5467-5484.
6. Tamura S., Tanimoto T., Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58:195-207.
7. Renegar K.B., Jackson G.D., Mestecky J. Invitro comparison of the biologic activities of monoclonal monomeric IgA, polymeric IgA, and secretory IgA. JImmunol 1998, 160:1219-1223.
8. Hagenaars N., Mastrobattista E., Glansbeek H., Heldens J., van den Bosch H., Schijns V., et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model. Vaccine 2008, 26:6555-6563.
9. Lavelle E.C. Generation of improved mucosal vaccines by induction of innate immunity. Cell Mol Life Sci 2005, 62:2750-2770.
10. Yuki Y., Kiyono H. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 2003, 13:293-310.
11. Adeola O.A., Adeniji J.A., Olugasa B.O. Detection of haemagglutination-inhibiting antibodies against human H1 and H3 strains of influenza A viruses in pigs in Ibadan, Nigeria. Zoonoses Public Health 2010, 57:e89-94.
12. Davis S.S., Illum L. Absorption enhancers for nasal drug delivery. Clin Pharm 2003, 42:1107-1128.
13. Soane R.J., Frier M., Perkins A.C., Jones N.S., Davis S.S., Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 1999, 178:55-65.
14. Slutter B., Hagenaars N., Jiskoot W. Rational design of nasal vaccines. JDrug Target 2008, 16:1-17.
15. Hagenaars N., Mania M., de Jong P., Que I., Nieuwland R., Slutter B., et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. JControl Release 2010, 144:17-24.
16. Luppi B., Bigucci F., Mercolini L., Musenga A., Sorrenti M., Catenacci L., et al. Novel mucoadhesive nasal inserts based on chitosan/hyaluronzite polyelectrolyte complexes for peptide and protein delivery. JPharm Pharmacol 2009, 61:151-157.
17. Illum L., Jabbal-Gill I., Hinchcliffe M., Fisher A.N., Davis S.S. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev 2001, 51:81-96.
18. Zaharoff D.A., Rogers C.J., Hance K.W., Schlom J., Greiner J.W. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine 2007, 25:2085-2094.
19. Alhalaweh A., Andersson S., Velaga S.P. Preparation of zolmitriptan-chitosan microparticles by spray drying for nasal delivery. Eur J Pharm Sci 2009, 38:206-214.
20. Wu J., Wei W., Wang L.Y., Su Z.G., Ma G.H. Athermosensitive hydrogel based on quaternized chitosan and poly(ethylene glycol) for nasal drug delivery system. Biomaterials 2007, 28:2220-2232.
21. Jang Y.J., Kim H.G., Koo T.W., Chung P.S. Localization of ZO-1 and E-cadherin in the nasal polyp epithelium. Eur Arch Otorhinolaryngol 2002, 259:465-469.
22. Ohtake K., Maeno T., Ueda H., Ogihara M., Natsume H., Morimoto Y. Poly-L-arginine enhances paracellular permeability via serine/threonine phosphorylation of ZO-1 and tyrosine dephosphorylation of occludin in rabbit nasal epithelium. Pharm Res 2003, 20:1838-1845.
23. Yoo M.K., Kang S.K., Choi J.H., Park I.K., Na H.S., Lee H.C., et al. Targeted delivery of chitosan nanoparticles to Peyer's patch using M cell-homing peptide selected by phage display technique. Biomaterials 2010, 31:7738-7747.
24. Wu J., Su Z.G., Ma G.H. Athermo- and pH-sensitive hydrogel composed of quaternized chitosan/glycerophosphate. Int J Pharm 2006, 315:1-11.
25. Taylor C.R. The total test approach to standardization of immunohistochemistry. Arch Pathol Lab Med 2000, 124:945-951.
26. Asanuma H., Thompson A.H., Iwasaki T., Sato Y., Inaba Y., Aizawa C., et al. Isolation and characterization of mouse nasal-associated lymphoid tissue. JImmunol Methods 1997, 202:123-131.
27. Natsume H., Iwata S., Ohtake K., Miyamoto M., Yamaguchi M., Hosoya K., et al. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. Int J Pharm 1999, 185:1-12.
28. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat Rev Immunol 2004, 4:699-710.
29. Renegar K.B., Small P.A., Boykins L.G., Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. JImmunol 2004, 173:1978-1986.
30. Barchfeld G.L., Hessler A.L., Chen M., Pizza M., Rappuoli R., Van Nest G.A. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine 1999, 17:695-704.
31. Lamblin C., Saelens T., Bergoin C., Wallaert B. The common mucosal immune system in respiratory disease. Rev Mal Respir 2000, 17:941-946.
32. Robinson H.L., Amara R.R. Tcell vaccines for microbial infections. Nat Med 2005, 11:S25-S32.